Rhapsido (Remibrutinib) 25mg – BTK Inhibitor for Chronic Urticaria

Rhapsido (Remibrutinib) 25mg is an innovative oral BTK inhibitor designed to treat adults with chronic spontaneous urticaria (CSU) unresponsive to antihistamines. By selectively blocking Bruton’s tyrosine kinase, it prevents the activation of mast cells, reducing histamine release and alleviating itching, swelling, and wheals. Developed by Novartis, Rhapsido offers a targeted, once-daily solution for persistent urticaria symptoms, helping patients regain comfort and quality of life.

Product Specifications

Active Ingredient

Remibrutinib

Indication

Indicated for adult patients with chronic spontaneous urticaria (CSU) who do not achieve symptom control with H1-antihistamines.

Strength

60 tablets

Packaging

25mg

Storage Temperature

Controlled room temperature

Why Choose Uno Healthcare?

Quality Assured

All products undergo rigorous quality checks and are sourced from certified manufacturers.

Global Shipping

Reliable logistics partners ensuring safe and timely delivery to your facility.

Expert Support

Dedicated team available to assist with product inquiries and order management.